This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smolewski, P. Articles by Zambrano, O. Search for Related Content PubMed PubMed Citation Articles by Smolewski, P. Articles by Zambrano, O.

Prognostic Factors in Hodgkin’s Disease: Multivariate Analysis of 327 Patients from a Single Institution

Departments of Haematology [P. S., T. R., E. K., M. B-M.], Pathology [A. P., E. C., O. Z.], and Chemotherapy [H. N.], Medical University of Lodz, 93-513 Lodz, Poland

On the basis of a retrospective study of 327 patients with Hodgkin’s disease (HD), the prognostic significance of several factors, accepted previously and recently proposed, has been analyzed with regard to response to treatment and the survival time. Multivariate regression analysis strongly decreased the number of potentially prognostic parameters. The only independent, pretreatment factors negatively influenced by either time of survival or response to treatment were the following: age at diagnosis of more than 45 years, advanced (IIIB/IV) clinical stage, poor clinical status according to Karnofsky’s scale (score less than 70), presence of systemic symptoms, mixed cellularity/lymphocyte depletion histological type, multisite peripheral nodal localization of the disease, abdominal lymphadenopathy, and large primary tumor mass (bulky disease). Short time to achieve complete remission (during the first four courses of chemotherapy) has proven to be significantly positive predictive factor. Cumulative dose of cytostatics lower than programmed was a significantly negative prognostic factor that correlated with a shorter time of survival. Lack of or a too-low dose of radiotherapy had the same predictive value. High activity of serum lactate dehydrogenase correlated moderately with poor response to the first-line treatment but did not influence the survival time. Other clinical, morphological, and biochemical parameters influenced neither the prognosis nor the response to treatment. Additionally, immunohistochemical examinations for proliferating cell nuclear antigen and the protein products of the p53 and bcl-2 genes were performed on the lymph nodes obtained from the patients with HD. High expression of proliferating cell nuclear antigen, p53, and BCL-2 correlated with poor response to the treatment and/or short time of survival. Statistical analysis has led us to the conclusion that the pretreatment expression of these oncoproteins can be taken into consideration as a new prognostic factor in HD.

This article has been cited by other articles:

				T. Alvaro, M. Lejeune, J. F. Garcia, Ma. T. Salvado, C. Lopez, R. Bosch, J. Jaen, P. Escriva, and L. E. Pons Tumor-Infiltrated Immune Response Correlates with Alterations in the Apoptotic and Cell Cycle Pathways in Hodgkin and Reed-Sternberg Cells Clin. Cancer Res., February 1, 2008; 14(3): 685 - 691. [Abstract] [Full Text] [PDF]

				S. Valsami, V. Pappa, D. Rontogianni, F. Kontsioti, E. Papageorgiou, J. Dervenoulas, T. Karmiris, S. Papageorgiou, N. Harhalakis, N. Xiros, et al. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4 Haematologica, October 1, 2007; 92(10): 1343 - 1350. [Abstract] [Full Text] [PDF]

				S. J. Sup, C. A. Alemany, B. Pohlman, P. Elson, S. Malhi, S. Thakkar, R. Steinle, and E. D. Hsi Expression of bcl-2 in Classical Hodgkin's Lymphoma: An Independent Predictor of Poor Outcome J. Clin. Oncol., June 1, 2005; 23(16): 3773 - 3779. [Abstract] [Full Text] [PDF]

				N. Spector, C. B. Milito, I. Biasoli, and J. C. Morais p53 Expression As a Prognostic Indicator in Hodgkin's Lymphoma J. Clin. Oncol., May 1, 2005; 23(13): 3158 - 3159. [Full Text] [PDF]

				J. F. Garcia In Reply: J. Clin. Oncol., May 1, 2005; 23(13): 3159 - 3160. [Full Text] [PDF]

				S. Hohaus, A. Di Ruscio, A. Di Febo, G. Massini, F. D'Alo', F. Guidi, G. Mansueto, M. T. Voso, and G. Leone Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma Clin. Cancer Res., March 15, 2005; 11(6): 2175 - 2179. [Abstract] [Full Text] [PDF]

				C. Montalban, J. F. Garcia, V. Abraira, L. Gonzalez-Camacho, M. M. Morente, J. L. Bello, E. Conde, M. A. Cruz, R. Garcia-Sanz, J. Garcia-Larana, et al. Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group J. Clin. Oncol., May 1, 2004; 22(9): 1664 - 1673. [Abstract] [Full Text] [PDF]

				S. Hohaus, G. Massini, F. D'Alo', F. Guidi, R. Putzulu, A. Scardocci, A. Rabi, A. L. Di Febo, M. T. Voso, and G. Leone Association between Glutathione S-Transferase Genotypes and Hodgkin's Lymphoma Risk and Prognosis Clin. Cancer Res., August 1, 2003; 9(9): 3435 - 3440. [Abstract] [Full Text] [PDF]

				R. S. Smith, Q. Chen, M. M. Hudson, M. P. Link, L. Kun, H. Weinstein, A. Billett, K. J. Marcus, N. J. Tarbell, and S. S. Donaldson Prognostic Factors for Children With Hodgkin's Disease Treated With Combined-Modality Therapy J. Clin. Oncol., May 15, 2003; 21(10): 2026 - 2033. [Abstract] [Full Text] [PDF]

				M. Provencio, C. Corbacho, C. Salas, I. Millan, P. Espana, F. Bonilla, and S. Ramon Cajal The Topoisomerase II{alpha} Expression Correlates with Survival in Patients with Advanced Hodgkin's Lymphoma Clin. Cancer Res., April 1, 2003; 9(4): 1406 - 1411. [Abstract] [Full Text] [PDF]

				G. Z. Rassidakis, L. J. Medeiros, T. P. Vassilakopoulos, S. Viviani, V. Bonfante, G. Nadali, M. Herling, M. K. Angelopoulou, R. Giardini, M. Chilosi, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens Blood, December 1, 2002; 100(12): 3935 - 3941. [Abstract] [Full Text] [PDF]

				S A Pileri, S Ascani, L Leoncini, E Sabattini, P L Zinzani, P P Piccaluga, A Pileri Jr, M Giunti, B Falini, G B Bolis, et al. Hodgkin's lymphoma: the pathologist's viewpoint J. Clin. Pathol., March 1, 2002; 55(3): 162 - 176. [Abstract] [Full Text] [PDF]